They've also listed "accelerated ageing" in the exploratory endpoints now aswell.
Original endpoints: "Standard & advanced cardiac markers including VO2Peak, m6A RNA levels, & anticancer efficacy"
New Endpoints: "Standard & advanced cardiac markers including VO2peak, m6A levels, accelerate ageing & anticancer efficacy"
Another poster recently called out the possibility of bisantrene protecting additional organs outside of the heart from the damage of anthracyclines. It would appear to me that the confirmation of the bisantrene mechanism of action has shown the Race team there are applications beyond just cardiotoxicity.
Also curious to note the cost has dropped from $11m to $9m??
RAC Price at posting:
$1.45 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)